Gain Therapeutics' GT-02287 shows promising efficacy and safety data, targeting both idiopathic and GBA1 Parkinson’s disease, with potential for substantial market impact and investor gains. The ...

Existing research indicates that the accuracy of a Parkinson's disease diagnosis hovers between 55% and 78% in the first five years of assessment. That's partly because Parkinson's sibling movement ...

In a heartfelt and revealing update, former NFL quarterback Brett Favre has candidly shared his ongoing struggle with Parkinson's disease. On a recent episode of his podcast, "Fourth and Favre," he ...

Existing research indicates that the accuracy of a Parkinson’s disease diagnosis hovers between 55% and 78% in the first five years of assessment. That’s partly because Parkinson’s sibling movement ...

Medicare covers deep brain stimulation (DBS) for eligible people diagnosed with essential tremors or idiopathic Parkinson’s disease to help reduce tremors and improve daily activities. To qualify for ...

Gain Therapeutics updates shareholders on the advancement of GT-02287 for Parkinson's disease, highlighting key clinical trial milestones and funding support. Gain Therapeutics, Inc. has announced ...

People with autism had a higher risk of developing Parkinson's disease early in life. The risk of Parkinson's before age 50 was four times higher in people with versus without autism. A Parkinson's ...